Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
- Markus EsslerAffiliated withDepartment of Nuclear Medicine, Technische Universität München
- , Florian C. GärtnerAffiliated withDepartment of Nuclear Medicine, Technische Universität München
- , Frauke NeffAffiliated withInstitute of Pathology, Helmholtz Zentrum München
- , Birgit BlechertAffiliated withDepartment of Nuclear Medicine, Technische Universität München
- , Reingard Senekowitsch-SchmidtkeAffiliated withDepartment of Nuclear Medicine, Technische Universität München
- , Frank BruchertseiferAffiliated withEuropean Commission, Joint Research Centre, Institute for Transuranium Elements
- , Alfred MorgensternAffiliated withEuropean Commission, Joint Research Centre, Institute for Transuranium Elements
- , Christof SeidlAffiliated withDepartment of Nuclear Medicine, Technische Universität München Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Targeted delivery of alpha-particle-emitting radionuclides is a promising novel option in cancer therapy. We generated stable conjugates of the vascular tumour-homing peptide F3 both with 225Ac and 213Bi that specifically bind to nucleolin on the surface of proliferating tumour cells. The aim of our study was to determine the therapeutic efficacy of 225Ac-DOTA-F3 in comparison with that of 213Bi-DTPA-F3.
ID50 values of 213Bi-DTPA-F3 and 225Ac-DOTA-F3 were determined via clonogenic assays. The therapeutic efficacy of both constructs was assayed by repeated treatment of mice bearing intraperitoneal MDA-MB-435 xenograft tumours. Therapy was monitored by bioluminescence imaging. Nephrotoxic effects were analysed by histology.
ID50 values of 213Bi-DTPA-F3 and 225Ac-DOTA-F3 were 53 kBq/ml and 67 Bq/ml, respectively. The median survival of control mice treated with phosphate-buffered saline was 60 days after intraperitoneal inoculation of 1 × 107 MDA-MB-435 cells. Therapy with 6 × 1.85 kBq of 225Ac-DOTA-F3 or 6 × 1.85 MBq of 213Bi-DTPA-F3 prolonged median survival to 95 days and 97 days, respectively. While F3 labelled with short-lived 213Bi (t 1/2 46 min) reduced the tumour mass at early time-points up to 30 days after treatment, the antitumour effect of 225Ac-DOTA-F3 (t 1/2 10 days) increased at later time-points. The difference in the fraction of necrotic cells after treatment with 225Ac-DOTA-F3 (43%) and with 213Bi-DTPA-F3 (36%) was not significant. Though histological analysis of kidney samples revealed acute tubular necrosis and tubular oedema in 10–30% of animals after treatment with 225Ac-DOTA-F3 or 213Bi-DTPA-F3, protein casts were negligible (2%), indicating only minor damage to the kidney.
Therapy with both 225Ac-DOTA-F3 and 213Bi-DTPA-F3 increased survival of mice with peritoneal carcinomatosis. Mild renal toxicity of both constructs favours future therapeutic application.
KeywordsTargeted radionuclide therapy Phage display Tumour-homing peptide F3 Peritoneal carcinomatosis α-emitters 225Ac and 213Bi
- Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis
European Journal of Nuclear Medicine and Molecular Imaging
Volume 39, Issue 4 , pp 602-612
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Targeted radionuclide therapy
- Phage display
- Tumour-homing peptide F3
- Peritoneal carcinomatosis
- α-emitters 225Ac and 213Bi
- Industry Sectors
- Author Affiliations
- 1. Department of Nuclear Medicine, Technische Universität München, Ismaninger Strasse 22, 81675, Munich, Germany
- 2. Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany
- 3. European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany